USFDA completes inspection at Aurobindo Pharma’s arm's Formulation facility in Telangana
The inspection concluded with 4 observations
The United States Food and Drug Administration (USFDA) has inspected Unit-I, a Formulation manufacturing facility of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, from February 16, 2026 to February 27, 2026.
The inspection concluded with 4 observations. The company will respond to the US FDA within the stipulated timelines. The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
